VigRX Plus tablets
27 March 2014
The Therapeutic Goods Administration (TGA) has tested a product labelled VigRX Plus tablets and found that it contains the undeclared substance tadalafil.
- Tadalafil should only be used on the advice of a medical practitioner and requires a prescription by a medical practitioner. The taking of medicines containing tadalafil without the advice of a medical practitioner poses a significant and serious health risk.
Photos of the product tested by TGA appear below.
A US based company, Leading Edge Marketing Inc. has contacted the TGA with the following information:
- the company is the formulator and distributor of a product called VigRX Plus tablets: and
- the sample of VigRX tablets tested by the TGA is a counterfeit sample.
VigRX Plus tablets (counterfeit or otherwise) have not been assessed by the TGA for quality, safety or efficacy.
VigRX Plus tablets are not approved for sale in Australia.
Information for consumers
- TGA recommends consumers stop taking any product that they have purchased labelled VigRX Plus tablets and take any remaining capsules to your local pharmacy for safe disposal.
- If you have any concerns arising from your use of this product, consult your health care practitioner.
Action the TGA is taking
The TGA is working with Australian Customs and Border Protection Service (ACBPS) to help stop future shipments of the VigRX Plus product that TGA has tested from entering Australia.
If these tablets are found at the border by ACBPS they will be seized and destroyed.
The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:
- may contain undisclosed and potentially harmful ingredients
- may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.
Report counterfeit medicines and medical devices
If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:
|Phone:||1800 020 653|
|Online:||Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products|
Content last updated: Friday, 5 September 2014
Web page last updated: Monday, 8 September 2014